JP2005513125A5 - - Google Patents

Download PDF

Info

Publication number
JP2005513125A5
JP2005513125A5 JP2003554632A JP2003554632A JP2005513125A5 JP 2005513125 A5 JP2005513125 A5 JP 2005513125A5 JP 2003554632 A JP2003554632 A JP 2003554632A JP 2003554632 A JP2003554632 A JP 2003554632A JP 2005513125 A5 JP2005513125 A5 JP 2005513125A5
Authority
JP
Japan
Prior art keywords
group
alkyl
moieties
aryl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003554632A
Other languages
English (en)
Japanese (ja)
Other versions
JP4439265B2 (ja
JP2005513125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/040453 external-priority patent/WO2003053915A2/en
Publication of JP2005513125A publication Critical patent/JP2005513125A/ja
Publication of JP2005513125A5 publication Critical patent/JP2005513125A5/ja
Application granted granted Critical
Publication of JP4439265B2 publication Critical patent/JP4439265B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003554632A 2001-12-20 2002-12-19 炎症性障害を治療する化合物 Expired - Fee Related JP4439265B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34233201P 2001-12-20 2001-12-20
PCT/US2002/040453 WO2003053915A2 (en) 2001-12-20 2002-12-19 Compounds for the treatment of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009188147A Division JP2010006817A (ja) 2001-12-20 2009-08-14 炎症性障害を治療する化合物

Publications (3)

Publication Number Publication Date
JP2005513125A JP2005513125A (ja) 2005-05-12
JP2005513125A5 true JP2005513125A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4439265B2 JP4439265B2 (ja) 2010-03-24

Family

ID=23341368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003554632A Expired - Fee Related JP4439265B2 (ja) 2001-12-20 2002-12-19 炎症性障害を治療する化合物
JP2009188147A Withdrawn JP2010006817A (ja) 2001-12-20 2009-08-14 炎症性障害を治療する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009188147A Withdrawn JP2010006817A (ja) 2001-12-20 2009-08-14 炎症性障害を治療する化合物

Country Status (15)

Country Link
US (3) US6838466B2 (cg-RX-API-DMAC7.html)
EP (1) EP1458676A2 (cg-RX-API-DMAC7.html)
JP (2) JP4439265B2 (cg-RX-API-DMAC7.html)
KR (1) KR20040068599A (cg-RX-API-DMAC7.html)
CN (1) CN1620424A (cg-RX-API-DMAC7.html)
AR (1) AR037929A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002357885A1 (cg-RX-API-DMAC7.html)
CA (1) CA2470620A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0500016A2 (cg-RX-API-DMAC7.html)
IL (1) IL162485A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04006031A (cg-RX-API-DMAC7.html)
PE (1) PE20030701A1 (cg-RX-API-DMAC7.html)
TW (1) TW200306809A (cg-RX-API-DMAC7.html)
WO (1) WO2003053915A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200404586B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020977A1 (en) * 2003-08-21 2005-03-10 Wisconsin Alumni Research Foundation Alpha-ketoglutarate potentiators of insulin secretion
ZA200605248B (en) 2003-12-15 2007-10-31 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
BRPI0507278A (pt) * 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7676590B2 (en) * 2004-05-03 2010-03-09 Microsoft Corporation Background transcoding
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2570694A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
US20060009491A1 (en) * 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
RU2007126842A (ru) * 2004-12-14 2009-01-27 Санофи-Авентис Дойчланд Гмбх (De) Применение замещенных производных циклопропановой кислоты для получения лекарственных средств для лечения метаболического синдрома
CN101282962A (zh) 2005-08-12 2008-10-08 先灵公司 用于治疗炎性疾病的化合物
EA200870019A1 (ru) 2005-12-05 2008-12-30 Инсайт Корпорейшн Лактамовые соединения и способы их применения
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2009537564A (ja) 2006-05-17 2009-10-29 インサイト・コーポレイション 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US8969342B2 (en) * 2009-03-20 2015-03-03 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
CN102241627B (zh) * 2010-05-14 2014-07-02 中国人民解放军总医院 脲类化合物及其医药用途
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
DK2790687T3 (en) * 2011-12-16 2018-11-19 Poseida Therapeutics Inc TRPC4 MODULATORS FOR USE IN TREATMENT OR PREVENTION OF Pain
EP3074375B1 (en) * 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
TW201625620A (zh) 2014-05-14 2016-07-16 美國科羅拉多州立大學 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
EP3930746A4 (en) 2019-02-25 2023-03-15 Emory University CHIMERA COMPOUNDS AND METHODS FOR MANAGEMENT OF NEUROLOGICAL DISORDERS OR CONDITIONS
KR20220164216A (ko) * 2021-06-04 2022-12-13 에스티팜 주식회사 신규한 에르고스텐올 유도체 및 이의 용도

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740412A (en) 1970-04-08 1973-06-19 Synvar Ass Imidazoline-3-oxide-1-oxyl derivatives
US3997223A (en) 1975-04-30 1976-12-14 Dynascan Corporation Apparatus and method for rejuvenating cathode ray tubes
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4267333A (en) 1979-09-26 1981-05-12 Union Carbide Agricultural Products Company, Inc. Preparation of 2-trifluoromethyl cinchoninic acids
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US4431661A (en) 1981-08-20 1984-02-14 American Cyanamid Company 5-Aryl-3-azabicyclo[3.2.0]heptan-6-one acetals, and analgesic use therefor
AU534404B2 (en) 1981-09-01 1984-01-26 American Cyanamid Company Cyclopropane derivatives
US4490055A (en) 1982-06-30 1984-12-25 International Business Machines Corporation Automatically adjustable delay function for timed typamatic
US4544665A (en) 1983-11-21 1985-10-01 American Cyanamid Company 1-Aryl-3-azabicyclo[3.2.0]heptanes
GB2200628A (en) 1987-02-06 1988-08-10 Shell Int Research Diphenyl ether herbicides
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JPH032797A (ja) 1989-05-30 1991-01-09 Meidensha Corp 音声合成装置の抑揚制御方式
WO1994000555A2 (en) 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US5120752A (en) 1989-12-28 1992-06-09 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
US5037853A (en) 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
US5114953A (en) 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
AU2807192A (en) 1991-10-02 1993-05-03 Smithkline Beecham Corporation Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity
JPH05262698A (ja) 1992-03-24 1993-10-12 Dainippon Ink & Chem Inc 光学活性トリフルオロメチルシクロプロパン誘導体、その合成中間体、それを含む液晶組成物及び液晶表示素子
US5525629A (en) 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
US5674901A (en) 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
CN1105799A (zh) 1993-03-18 1995-07-26 大制药株式会社 作为基质金属蛋白酶抑制剂的喹诺酮衍生物
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
JPH072797A (ja) 1993-04-19 1995-01-06 Sankyo Co Ltd コラゲナーゼ阻害剤
GB9311282D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
FI960803L (fi) 1993-08-23 1996-04-22 Immunex Corp TNF-alfa-sekreetion inhibiittoreita
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
JP3297053B2 (ja) 1994-01-20 2002-07-02 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
AU678884B2 (en) 1994-01-22 1997-06-12 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
WO1995024501A1 (en) 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
US5817822A (en) 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
US5840698A (en) 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
JP2902318B2 (ja) 1994-12-28 1999-06-07 呉羽化学工業株式会社 エスクレチン誘導体、その製造方法及びマトリックスメタロプロテアーゼ阻害剤
US5703092A (en) 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB2303130A (en) 1995-07-10 1997-02-12 Secr Defence Cyclic oligomers of substituted cyclic ethers
GB9514867D0 (en) 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EP0848957A1 (en) 1995-09-08 1998-06-24 Kanebo Ltd. Fas LIGAND SOLUBILIZATION INHIBITOR
KR100472752B1 (ko) 1995-10-05 2006-01-27 다윈 디스커버리 리미티드 금속단백질 가수분해 효소 및 티엔에프 유리에 대한 억제제로서의 티오-치환펩티드
JP2000502050A (ja) 1995-11-14 2000-02-22 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー メタロプロテアーゼ阻害剤としての新規なマクロ環状化合物
US5665777A (en) 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EA003294B1 (ru) 1995-12-08 2003-04-24 Агурон Фармасьютикалс, Инк. Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
JPH09202774A (ja) * 1996-01-25 1997-08-05 Green Cross Corp:The 2−アリールキノリン類およびその製造方法
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1997040031A1 (en) 1996-04-23 1997-10-30 Pharmacia & Upjohn Company Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
WO1998002557A2 (en) 1996-07-12 1998-01-22 Schering Corporation MAMMALIAN TNF-α CONVERTASES
US5853977A (en) 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
ATE233552T1 (de) 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
HUP0000505A3 (en) 1996-08-28 2001-12-28 Procter & Gamble Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them
CN1228771A (zh) 1996-08-28 1999-09-15 普罗克特和甘保尔公司 1,3-二杂环金属蛋白酶抑制剂
HUP9903916A3 (en) 1996-08-28 2001-06-28 Procter And Gamble Co Cincinna Phosphinic acid amides and pharmaceutical compositions containing the same
ATE226573T1 (de) 1996-08-28 2002-11-15 Procter & Gamble Heterozyklische metalloproteaseinhibitoren
KR20000068415A (ko) 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
KR100338610B1 (ko) 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
PT928291E (pt) 1996-09-19 2003-03-31 Aventis Pharma Inc Derivados de 3-mercaptoacetilamino-1,5-substituido-2-oxo-azepano uteis como inibidores de metaloproteinases matriciais
ID21897A (id) 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
WO1998015525A1 (en) 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Hydroxamic acids
DE69709160T2 (de) 1996-10-16 2002-08-14 American Cyanamid Co., Madison Herstellung und anwendung von ortho-sulfonamido-aryl-hydroxamsäuren als matrix-metalloproteinase- und tace-inhibitoren
KR20000049197A (ko) 1996-10-16 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 매트릭스 메탈로프로테이나제 및 종양 괴사 인자-α 전환 효소억제제로서의 오르토-설폰아미도 헤테로아릴 하이드록삼산의 제조 및 용도
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
NZ335053A (en) 1996-10-16 2000-10-27 American Cyanamid Co Beta-sulfonamido hydroxamic acids or ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase MMP and TACE (tumour necrosis factor, TNF, alpha converting enzyme) inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
AU743901B2 (en) 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
GB9621814D0 (en) 1996-10-19 1996-12-11 British Biotech Pharm Metalloproteinase inhibitors
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
MY117687A (en) 1996-10-31 2004-07-31 Bayer Corp Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors
JPH10130217A (ja) 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
GB9624817D0 (en) 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
US5840974A (en) 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
WO1998027069A1 (en) 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ZA9820B (en) 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
ZA9818B (en) 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
JPH10204054A (ja) 1997-01-21 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
JPH10204059A (ja) 1997-01-22 1998-08-04 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
JP3563411B2 (ja) 1997-01-23 2004-09-08 エフ・ホフマン−ラ ロシュ アーゲー スルファミド−メタロプロテアーゼ阻害剤
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
SK112899A3 (en) 1997-02-26 2001-05-10 Pfizer Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of mip-1-alpha binding to its ccr1 receptor
KR20000075681A (ko) 1997-02-26 2000-12-26 그레이엄 브레레톤, 레슬리 에드워즈 메탈로프로테아제 억제제로서의 후위 히드록사메이트 유도체
AU748998B2 (en) 1997-02-27 2002-06-13 Wyeth Holdings Corporation N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
CA2281570C (en) 1997-03-11 2003-09-23 Les Laboratoires Aeterna Inc. Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
JP2001518090A (ja) 1997-03-28 2001-10-09 ゼネカ リミテッド 腫瘍壊死因子の阻害に有用な複素環により置換したヒドロキサム酸
EP0973748A1 (en) 1997-04-01 2000-01-26 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AT404904B (de) 1997-04-03 1999-03-25 Prior Eng Ag Vorrichtung zur kontinuierlichen annularen chromatographie
GB9707333D0 (en) 1997-04-11 1997-05-28 British Biotech Pharm Metalloproteinase inhibitors
ATE210639T1 (de) 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
AU7294098A (en) 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5804581A (en) 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
GB9710490D0 (en) 1997-05-21 1997-07-16 British Biotech Pharm Metalloproteinase inhibitors
EP0887077A1 (de) 1997-06-27 1998-12-30 Boehringer Mannheim Gmbh Verwendung von Azulenderivaten als Metalloproteaseinhibitoren
CA2265671A1 (en) 1997-07-10 1999-01-21 Daniela Jabes Matrix metalloproteinase inhibitors
CA2297988A1 (en) 1997-08-04 1999-02-11 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
DE69805473T2 (de) 1997-08-08 2003-01-16 Pfizer Products Inc., Groton Arylsulfonylaminohydroxamsäurederivate
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
WO1999018079A1 (en) 1997-10-06 1999-04-15 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
CN1138760C (zh) 1997-10-06 2004-02-18 惠氏控股公司 作为基质金属蛋白酶和tace抑制剂的邻亚磺酰氨基二环杂芳基异羟肟酸的制备和用途
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
CA2308361A1 (en) 1997-11-12 1999-05-20 Andrew Douglas Baxter Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GB9723905D0 (en) 1997-11-12 1998-01-07 Chiroscience Ltd Heterocyclic compounds having MMP and TNF inhibitory activity
WO1999024399A1 (en) 1997-11-12 1999-05-20 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
HUP0002811A3 (en) 1997-11-13 2002-11-28 British Biotech Pharm Succinamide derivative as metalloproteinase inhibitors and pharmaceutical compositions containing it
FR2771095B1 (fr) 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2200154C2 (ru) 1997-12-12 2003-03-10 Дайичи Файн Кемикал Ко., Лтд. Новые ингибиторы металлопротеиназ
EP0922702A1 (de) 1997-12-13 1999-06-16 Roche Diagnostics GmbH Neue Azulenderivate und diese enthaltende Arzneimittel
US6107291A (en) 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
DE69830513T2 (de) 1997-12-22 2006-03-16 Bayer Pharmaceuticals Corp., West Haven HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
EP1044173A4 (en) 1997-12-23 2005-03-09 Spectran Corp LARGE SCALE MANUFACTURING PROCESS OF OPTICAL FIBER PREFORMS WITH IMPROVED CHARACTERISTICS
US6071903A (en) 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
CN1293663A (zh) 1998-01-27 2001-05-02 美国氰胺公司 为基质金属蛋白酶抑制剂的2,3,4,5-四氢-1h-[1,4]苯并二氮杂䓬-3-异羟肟酸
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
DE69934094T2 (de) 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
PL342009A1 (en) 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
IL137147A0 (en) 1998-02-06 2001-07-24 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
CN1213021C (zh) 1998-02-19 2005-08-03 惠氏控股公司 作为基质金属蛋白酶抑制剂的 n -羟基- 2 - (烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基 ) - 3 -取代的烷
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
DE69917124T2 (de) 1998-04-10 2005-05-12 Pfizer Products Inc., Groton Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
EP1077974A1 (en) 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
BR9910678A (pt) 1998-05-14 2001-10-02 Du Pont Pharm Co Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19831980A1 (de) 1998-07-16 2000-01-20 Hoechst Marion Roussel De Gmbh Sulfonylaminophosphin- und phosphonsäurederivate
US6350885B1 (en) 1998-07-30 2002-02-26 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
WO2000012082A1 (en) 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
EP1121118A4 (en) 1998-08-26 2002-09-11 Glaxo Group Ltd FORMAMIDE-BASED THERAPEUTIC AGENTS
AU5688999A (en) 1998-08-26 2000-03-21 Glaxo Group Limited Formamide compounds as therapeutic agents
US6479502B1 (en) 1998-08-29 2002-11-12 British Biotech Pharmaceuticals Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
WO2000015603A1 (en) 1998-09-11 2000-03-23 Ajinomoto Co., Inc. Benzene derivatives and medicinal use thereof
AU5654399A (en) 1998-09-22 2000-04-10 Ishihara Sangyo Kaisha Ltd. Medical composition containing nitroetheneamine derivative or salt thereof as active constituent
ES2205944T3 (es) 1998-10-23 2004-05-01 Dow Agrosciences Llc Compuestos de 3-(fenil sustituido)-5-(ciclopropil sustituido)-1,2,4-triazol.
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
GB9826153D0 (en) 1998-11-27 1999-01-20 Hoffmann La Roche Hydrazine derivatives
CN1132819C (zh) 1998-12-11 2003-12-31 霍夫曼-拉罗奇有限公司 作为TNF-α抑制剂的环状肼衍生物
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
WO2000037433A1 (en) 1998-12-18 2000-06-29 Abbott Laboratories Inhibitors of matrix metalloproteinases
JP2002536964A (ja) 1998-12-22 2002-11-05 サブサイダリー ナンバースリー インコーポレイテッド ヒト免疫不全ウイルスに対する遺伝子抑制エレメント
AU1836900A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
CA2358939A1 (en) 1998-12-31 2000-07-13 Joseph P. Burkhart 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
CA2357874A1 (en) 1999-01-07 2000-07-13 Fujisawa Pharmaceutical Co., Ltd. Cyclic compound
AU2500800A (en) 1999-01-14 2000-08-01 Bruce M. Boman Immunoassays to detect diseases or disease susceptibility traits
FR2788525B1 (fr) 1999-01-19 2002-11-29 Commissariat Energie Atomique Pseudo-peptides phosphiniques, utilisables comme inhibiteurs des metalloproteases a zinc matricielles
US6294539B1 (en) 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AR022423A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022424A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
ATE280152T1 (de) 1999-01-27 2004-11-15 Wyeth Corp Acetylenische sulfonamid-thiol-tace-inhibitoren
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR035478A1 (es) 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
AR022422A1 (es) 1999-01-27 2002-09-04 American Cyanamid Co Inhibidores de tace acetilenicos de acido hidroxamico de heteroarilfulfonamida y amida del acido fosfinico
WO2000046189A1 (en) 1999-02-02 2000-08-10 Shionogi & Co., Ltd. Sulfonamide derivatives having cyclic structures
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
DE60003863T2 (de) 1999-03-31 2004-04-22 Pfizer Products Inc., Groton Dioxocyclopentylhydroxamsäure
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
AUPP982399A0 (en) 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
AU4249700A (en) 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
MXPA01011762A (es) 1999-05-17 2002-04-24 Daiichi Fine Chem Co Ltd Derivados novedosos de acido hidroxamico.
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
GB9922825D0 (en) 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6632667B1 (en) 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
JP4798921B2 (ja) 2000-03-06 2011-10-19 バイオシーク インコーポレーティッド 機能相同性スクリーニング
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
ATE260272T1 (de) 2000-03-17 2004-03-15 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
EP1282614B1 (en) 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamic acid derivatives
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
US20040029928A1 (en) 2000-08-31 2004-02-12 Terukage Hirata Novel propenohydroxamic acid derivatives
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
SE519050C2 (sv) 2001-05-28 2003-01-07 Fazer Ab Oy Karl Påfyllnadsanordning för varor
US6770647B2 (en) 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
AU2002341715A1 (en) 2001-09-17 2003-04-01 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)

Similar Documents

Publication Publication Date Title
JP2010006817A (ja) 炎症性障害を治療する化合物
JP2004535447A5 (cg-RX-API-DMAC7.html)
JP4129286B2 (ja) 新規チアゾリジン−4−オン誘導体
AR040803A1 (es) Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2008505117A5 (cg-RX-API-DMAC7.html)
JP2008501691A5 (cg-RX-API-DMAC7.html)
JP2008504301A5 (cg-RX-API-DMAC7.html)
RU2002127682A (ru) Замещенные бета-карболины
HRP20250099T1 (hr) Agonisti receptora glp-1 i njihova upotreba
JP2017114880A5 (cg-RX-API-DMAC7.html)
JP2007502814A5 (cg-RX-API-DMAC7.html)
JP2015502387A5 (cg-RX-API-DMAC7.html)
PL181694B1 (pl) Pochodne cyjanidowe PL PL PL
JP2002543185A5 (cg-RX-API-DMAC7.html)
JP2022519239A5 (cg-RX-API-DMAC7.html)
CA2560523A1 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
JP2021528451A5 (cg-RX-API-DMAC7.html)
JP2012529535A5 (cg-RX-API-DMAC7.html)
JP2022519696A5 (cg-RX-API-DMAC7.html)
JPH0670056B2 (ja) 新規テトラオキソ−ジアザビシクロ−(3,3,1)−ノナンおよびその製法
JP2018526421A5 (cg-RX-API-DMAC7.html)
JP2008540454A5 (cg-RX-API-DMAC7.html)
JP2021528405A5 (cg-RX-API-DMAC7.html)
JP2007503432A5 (cg-RX-API-DMAC7.html)